Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DVAX
stocks logo

DVAX

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
86.66M
+17.44%
--
--
94.41M
+17.08%
--
--
81.31M
+12.88%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Dynavax Technologies Corporation (DVAX) for FY2025, with the revenue forecasts being adjusted by 2.34% over the past three months. During the same period, the stock price has changed by -3.55%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.34%
In Past 3 Month
Stock Price
Go Down
down Image
-3.55%
In Past 3 Month
3 Analyst Rating
up Image0
Wall Street analysts forecast DVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVAX is 28.00 USD with a low forecast of 25.00 USD and a high forecast of 31.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 10.860
sliders
Low
25.00
Averages
28.00
High
31.00
up Image0
Current: 10.860
sliders
Low
25.00
Averages
28.00
High
31.00
Goldman Sachs
Paul Choi
Strong Sell
Maintains
$12 → $10
2025-04-17
Reason
Goldman Sachs
Paul Choi
Price Target
$12 → $10
2025-04-17
Maintains
Strong Sell
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$31
2025-02-21
Reason
HC Wainwright & Co.
Edward White
Price Target
$31
2025-02-21
Reiterates
Strong Buy
Reason
Citizens Capital Markets
Jason Butler
Buy
Maintains
$29 → $33
2025-02-21
Reason
Citizens Capital Markets
Jason Butler
Price Target
$29 → $33
2025-02-21
Maintains
Buy
Reason
Citizens JMP raised the firm's price target on Dynavax to $33 from $29 and keeps an Outperform rating on the shares. Dynavax reported fiscal 2024 results in line with January's preannouncement, and management remains optimistic on the potential for bringing in value-add, late-stage assets in the infectious disease space as the best way to maximize the value of its hepatitis B vaccine, HEPLISAV-B, the analyst tells investors in a research note. Management also continues to seek out assets in the infectious disease space, and believes there are viable assets, the firm notes.
Goldman Sachs
Paul Choi
Hold
to
Strong Sell
Downgrades
$15 → $12
2025-02-11
Reason
Goldman Sachs
Paul Choi
Price Target
$15 → $12
2025-02-11
Downgrades
Hold
to
Strong Sell
Reason
Goldman Sachs downgraded Dynavax to Sell from Neutral with a price target of $12, down from $15. The evolving competitive landscape in shingles vaccination lowers the potential of the company's Z-1018 program and increases long-term revenue uncertainty, the analyst tells investors in a research note. In addition, the firm says " unpredictable demand patters" for repeat hepatitis-B vaccinations in the 2030s, could cloud the long term outlook for Heplisav-B beyond its peak sales despite its market share gains. Goldman says Dynavax now ranks in the lowest quintile for potential upside in its coverage group.
HC Wainwright & Co.
Edward White
Strong Buy
Maintains
$29 → $31
2025-01-14
Reason
HC Wainwright & Co.
Edward White
Price Target
$29 → $31
2025-01-14
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$29
2024-11-08
Reason
HC Wainwright & Co.
Edward White
Price Target
$29
2024-11-08
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Dynavax Technologies Corp (DVAX.O) is 23.19, compared to its 5-year average forward P/E of -5.97. For a more detailed relative valuation and DCF analysis to assess Dynavax Technologies Corp 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.97
Current PE
23.19
Overvalued PE
116.34
Undervalued PE
-128.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
60.59
Current EV/EBITDA
43.76
Overvalued EV/EBITDA
258.36
Undervalued EV/EBITDA
-137.18

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
4.53
Current PS
3.83
Overvalued PS
6.76
Undervalued PS
2.31

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 122.6% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

DVAX News & Events

Events Timeline

(ET)
2025-06-11
11:04:47
Dynavax stockholders elect all director nominees at Annual Meeting
select
2025-06-09 (ET)
2025-06-09
07:45:28
Dynavax urges stockholders vote 'FOR' director nominees
select
2025-06-04 (ET)
2025-06-04
09:31:38
Dynavax shareholder announces Glass Lewis recommendation for board change
select
Sign Up For More Events
Sign Up For More Events

News

Preview
9.5
07-30PRnewswire
Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

  • Upcoming Financial Results Announcement: Dynavax Technologies Corporation will report its second quarter 2025 financial results on August 7, 2025, after U.S. market close and will host a conference call at 4:30 p.m. ET.

  • Company Overview: Dynavax is a biopharmaceutical company focused on developing innovative vaccines, including HEPLISAV-B for hepatitis B and the CpG 1018 adjuvant used in various COVID-19 vaccines.

Preview
4.5
07-12NASDAQ.COM
After Hours Most Active for Jul 11, 2025 : HPE, AAPL, ABVE, INTC, CMCSA, NVDA, DVAX, PFE, WMB, LION, KO, JBS

  • NASDAQ 100 After Hours Performance: The NASDAQ 100 is down -9.83 to 22,770.77 with a total after-hours volume of 110,913,091 shares traded, featuring active stocks like Hewlett Packard Enterprise (HPE) unchanged at $20.72 and Apple Inc. (AAPL) down -0.51 at $210.65.

  • Stock Highlights: Notable movements include NVIDIA Corporation (NVDA) up +0.08 at $165.00, while other companies like Pfizer (PFE) and Comcast (CMCSA) remain mostly unchanged, with various stocks showing their current last sale percentages relative to target prices.

Preview
3.0
06-23NASDAQ.COM
How The Parts Add Up: VIOO Headed For $118

  • ETF Analysis: The Vanguard S&P Small-Cap 600 ETF (VIOO) has an implied analyst target price of $118.23, indicating a potential upside of 20.32% from its current trading price of $98.27.

  • Stock Performance Insights: Notable underlying holdings such as Arrowhead Pharmaceuticals, Dynavax Technologies, and Simulations Plus show significant upside potential based on analyst targets, raising questions about the validity and optimism of these forecasts.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Dynavax Technologies Corp (DVAX) stock price today?

The current price of DVAX is 10.86 USD — it has decreased -1.09 % in the last trading day.

arrow icon

What is Dynavax Technologies Corp (DVAX)'s business?

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

arrow icon

What is the price predicton of DVAX Stock?

Wall Street analysts forecast DVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVAX is 28.00 USD with a low forecast of 25.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Dynavax Technologies Corp (DVAX)'s revenue for the last quarter?

Dynavax Technologies Corp revenue for the last quarter amounts to 68.16M USD, increased 34.21 % YoY.

arrow icon

What is Dynavax Technologies Corp (DVAX)'s earnings per share (EPS) for the last quarter?

Dynavax Technologies Corp. EPS for the last quarter amounts to -0.77 USD, increased 1000.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Dynavax Technologies Corp (DVAX)'s fundamentals?

The market is revising Upward the revenue expectations for Dynavax Technologies Corporation (DVAX) for FY2025, with the revenue forecasts being adjusted by 2.34% over the past three months. During the same period, the stock price has changed by -3.55%.
arrow icon

How many employees does Dynavax Technologies Corp (DVAX). have?

Dynavax Technologies Corp (DVAX) has 405 emplpoyees as of August 03 2025.

arrow icon

What is Dynavax Technologies Corp (DVAX) market cap?

Today DVAX has the market capitalization of 1.30B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free